3020 Children's Way
San Diego, CA 92123
Rady Children's Specialists of San Diego
Columbia University College of Physicians and Surgeons
University of Chicago Comer Children's Hospital
Children's Memorial Hospital
Dr. Peter Zage is an attending hematologist/oncologist at Rady Children's Hospital-San Diego and an associate professor-in-residence in pediatric oncology at UC San Diego Moores Cancer Center.
Dr. Zage received his bachelor's degree in biology from Johns Hopkins University and earned his medical and doctoral degrees from Columbia University in New York. He then completed a residency in pediatrics at the University of Chicago Children's Hospital and a fellowship in pediatric hematology/oncology at Children's Memorial Hospital (now Lurie Children's Hospital) before starting his first faculty position as an assistant professor at the University of Texas MD Anderson Cancer Center. He was an assistant professor in the Section of Pediatric Hematology/Oncology at Baylor College of Medicine and Texas Children's Cancer Center prior to joining Rady Children's and UC San Diego in 2016.
Dr. Zage is an expert in the treatment of the pediatric solid tumors neuroblastoma and retinoblastoma, and his laboratory is focused on developing novel treatments and identifying novel targets for therapies for children with solid tumors. His primary laboratory projects include studies to better understand the pathways involved in the regulation of growth factor receptor trafficking and degradation in tumor cells and their role in tumor growth and treatment response in addition to studies to identify novel therapeutic targets and novel agents to use in combination with established therapies.
Dr. Zage's laboratory has identified a key role for the ubiquitin ligase UBE4B in the regulation of receptor trafficking in neuroblastoma tumor cells, and he has also identified several promising novel targeted agents that have been translated into early phase clinical trials for children with relapsed and refractory solid tumors.
The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma.
Foster JH, Barbieri E, Zhang L, Scorsone KA, Moreno-Smith M, Zage P, Horton TM
Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors.
Whittle SB, Smith V, Silverstein A, Parmeter M, Minard CG, Bernhardt MB, Zage PE, Venkatramani R, Nuchtern JG, Heczey A, Russell HV, Shohet JM, Foster JH
Characterization of G-CSF receptor expression in medulloblastoma.
Paul MR, Huo Y, Liu A, Lesperance J, Garancher A, Wechsler-Reya RJ, Zage PE
Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways.
Subramonian D, Phanhthilath N, Rinehardt H, Flynn S, Huo Y, Zhang J, Messer K, Mo Q, Huang S, Lesperance J, Zage PE
Mechanisms of Efficacy of the FGFR1-3 Inhibitor AZD4547 in Pediatric Solid Tumor Models.
Phanhthilath N, Hakim S, Su C, Liu A, Subramonian D, Lesperance J, Zage PE
The Potential Functional Roles of NME1 Histidine Kinase Activity in Neuroblastoma Pathogenesis.
Adam K, Lesperance J, Hunter T, Zage PE
A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.
Lewis EC, Kraveka JM, Ferguson W, Eslin D, Brown VI, Bergendahl G, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Zage P, Rawwas J, Rich M, Lorenzi E, Broglio K, Berry D, Saulnier Sholler GL
Sociodemographic and clinical characteristics associated with vitamin D status in newly diagnosed pediatric cancer patients.
Aristizabal P, Sherer M, Perdomo BP, Castelao E, Thornburg CD, Proudfoot J, Jacobs E, Newfield RS, Zage P, Roberts W, Martinez ME
The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo.
Flynn SM, Lesperance J, Macias A, Phanhthilath N, Paul MR, Kim JW, Tamayo P, Zage PE
Maintenance DFMO Increases Survival in High Risk Neuroblastoma.
Sholler GLS, Ferguson W, Bergendahl G, Bond JP, Neville K, Eslin D, Brown V, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Parikh NS, Eshun F, Zage P, Rawwas J, Sencer S, Pankiewicz D, Quinn M, Rich M, Junewick J, Kraveka JM
Overview and recent advances in the treatment of neuroblastoma.
Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE
The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.
Whittle SB, Patel K, Zhang L, Woodfield SE, Du M, Smith V, Zage PE
CD114: A New Member of the Neural Crest-Derived Cancer Stem Cell Marker Family.
Zage PE, Whittle SB, Shohet JM
Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine.
Du M, Zhang L, Scorsone KA, Woodfield SE, Zage PE
Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B.
Woodfield SE, Guo RJ, Liu Y, Major AM, Hollingsworth EF, Indiviglio S, Whittle SB, Mo Q, Bean AJ, Ittmann M, Lopez-Terrada D, Zage PE
Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.
Woodfield SE, Zhang L, Scorsone KA, Liu Y, Zage PE
A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation.
Whittle SB, Reyes S, Du M, Gireud M, Zhang L, Woodfield SE, Ittmann M, Scheurer ME, Bean AJ, Zage PE
Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
Zhang L, Scorsone K, Woodfield SE, Zage PE
CD114 Expression Mediates Melanoma Tumor Cell Growth and Treatment Resistance.
Zhang L, Agarwal S, Shohet JM, Zage PE
mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling.
Zhang H, Dou J, Yu Y, Zhao Y, Fan Y, Cheng J, Xu X, Liu W, Guan S, Chen Z, shi Y, Patel R, Vasudevan SA, Zage PE, Zhang H, Nuchtern JG, Kim ES, Fu S, Yang J
The novel kinase inhibitor EMD1214063 is effective against neuroblastoma.
Scorsone K, Zhang L, Woodfield SE, Hicks J, Zage PE
Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies.
Brown BS, Patanam T, Mobli K, Celia C, Zage PE, Bean AJ, Tasciotti E
Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounterâ„¢ system.
Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM, Zage PE, Hicks MJ, Shimada H, Suganuma R, Park JR, So S, London WB, Pytel P, Maclean KH, Cohn SL
See the full listing of this physician's publications on PubMed, a service of the National Library of Medicine.
PubMed is a third-party website and not affiliated with Rady Children's Hospital-San Diego.
Rady Children's updates the Doctor Finder annually. We are not responsible for omissions or errors. Prior to making an appointment, please be sure to check with your health plan to confirm coverage. If you see an error or omission on a physician's profile page, please contact us at firstname.lastname@example.org.